Brainstorm Cell Therapeutics’ (BCLI) Buy Rating Reaffirmed at Maxim Group

Brainstorm Cell Therapeutics (NASDAQ:BCLI)‘s stock had its “buy” rating restated by Maxim Group in a research note issued to investors on Tuesday, AnalystRatings.com reports. They currently have a $9.00 price objective on the biotechnology company’s stock. Maxim Group’s price target would suggest a potential upside of 126.70% from the stock’s previous close.

The analysts wrote, “Brainstorm reported 1Q19 with a net loss of ~($5M) and $6.2M in cash on the balance sheet, excluding commitments from the CIRM and IIA grants of a combined $4M.””

Shares of NASDAQ:BCLI opened at $3.97 on Tuesday. Brainstorm Cell Therapeutics has a 1-year low of $2.92 and a 1-year high of $5.35. The company has a current ratio of 0.97, a quick ratio of 1.65 and a debt-to-equity ratio of 9.34.



Large investors have recently made changes to their positions in the company. ETF Managers Group LLC grew its holdings in shares of Brainstorm Cell Therapeutics by 75.8% during the 4th quarter. ETF Managers Group LLC now owns 66,797 shares of the biotechnology company’s stock worth $237,000 after purchasing an additional 28,809 shares in the last quarter. Renaissance Technologies LLC grew its holdings in shares of Brainstorm Cell Therapeutics by 16.0% during the 3rd quarter. Renaissance Technologies LLC now owns 133,900 shares of the biotechnology company’s stock worth $511,000 after purchasing an additional 18,500 shares in the last quarter. Delek Group Ltd. acquired a new stake in shares of Brainstorm Cell Therapeutics during the 1st quarter worth approximately $183,000. CIBC Private Wealth Group LLC grew its holdings in shares of Brainstorm Cell Therapeutics by 349.9% during the 1st quarter. CIBC Private Wealth Group LLC now owns 67,484 shares of the biotechnology company’s stock worth $293,000 after purchasing an additional 52,484 shares in the last quarter. Finally, Morgan Stanley grew its holdings in shares of Brainstorm Cell Therapeutics by 104.1% during the 1st quarter. Morgan Stanley now owns 19,995 shares of the biotechnology company’s stock worth $87,000 after purchasing an additional 10,200 shares in the last quarter. 8.30% of the stock is currently owned by institutional investors.

Brainstorm Cell Therapeutics Company Profile

Brainstorm Cell Therapeutics Inc, a biotechnology company, engages in the development and commercialization of central nervous system (CNS) adult stem cell therapies designed to address the unmet medical needs of patients with debilitating neurodegenerative diseases. The company holds rights to develop and commercialize its NurOwn technology that utilizes a patient's own cells, which are engineered outside the body, to produce and secrete factors known to promote neuronal survival.

Featured Article: Recession

Receive News & Ratings for Brainstorm Cell Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Brainstorm Cell Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.